N-(4-hydroxyphenyl)arachidonylamide (AM404)

Subscribe to Selected New Research on N-(4-hydroxyphenyl)arachidonylamide

30 relevant articles (2 outcomes, 7 trials/studies) found for this Bio-Agent

Also Known As:

AM404; AM 404; AM-404

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Fatty Acids: 4922

Unsaturated Fatty Acids: 2398

Eicosanoids: 1178

Arachidonic Acids: 78

N-(4-hydroxyphenyl)arachidonylamide: 30

Essential Fatty Acids: 472

Arachidonic Acids: 78

N-(4-hydroxyphenyl)arachidonylamide: 30

Arachidonic Acids: 78

N-(4-hydroxyphenyl)arachidonylamide: 30

Experts

1.	Iacono, A: 2 articles (03/2008 - 06/2006)
2.	Raso, G Mattace: 2 articles (03/2008 - 06/2006)
3.	Calignano, A: 2 articles (03/2008 - 06/2006)
4.	Meli, R: 2 articles (03/2008 - 06/2006)
5.	La Rana, G: 2 articles (03/2008 - 06/2006)
6.	Russo, R: 2 articles (03/2008 - 06/2006)
7.	Piomelli, D: 2 articles (03/2008 - 06/2006)
8.	D'Agostino, G: 1 article (03/2008)
9.	Sasso, O: 1 article (03/2008)
10.	Vaughan, Christopher W: 1 article (11/2007)

Related Diseases

1.	Hyperalgesia 08/01/2006 - "Daily treatment with AM404 prevented, time- and dose-dependently, the development of thermal hyperalgesia and mechanical allodynia in neuropathic rats. " 11/01/2009 - "4. The results of the present study indicate that systemic administration of UCM707 and AM404 is effective in ameliorating chemical hyperalgesia in STZ-diabetic rats. " 11/01/2009 - "At 10 and 50 mg/kg, both UCM707 and AM404 reversed chemical hyperalgesia in diabetic rats. " 10/01/2006 - "Repeated treatment with either (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate or AM404 reverted the hyperalgesia and enhanced serotonergic activity induced by CCI in a way attenuated by N-piperidino-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-3-pyrazolecarboxamide, a selective cannabinoid subtype 1 (CB1) receptor antagonist. " 10/01/2006 - "We used a model of neuropathic pain consisting of rats with chronic constriction injury (CCI) of the sciatic nerve, in order to investigate whether endocannabinoid levels are altered in the dorsal raphe (DR) and to assess the effect of repeated treatment with (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate, a synthetic cannabinoid agonist, or N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (AM404), an inhibitor of endocannabinoid reuptake, on DR serotonergic neuronal activity and on behavioural hyperalgesia. " Order ALL the reference details at left...
2.	Parkinsonian Disorders (Parkinsonism) 06/01/2004 - "Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function." Order ALL the reference details at left...
3.	Pain (Aches) 06/04/2007 - "These results suggest that AM404 could be a useful drug to reduce inflammatory pain in our experimental model and that cannabinoid CB(2) receptor and vanilloid TRPV-1 receptor, and to a lesser extent, the cannabinoid CB(1) receptor are involved." 06/04/2007 - "AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain." 11/01/2007 - "In the present study, we examined the effect of acute administration of the anandamide transport inhibitor AM404 in rat models of chronic neuropathic and inflammatory pain. " 01/31/2005 - "In this study we evaluated the effects of administrating N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (AM404), an inhibitor of anandamide reuptake and monitoring the expression of c-fos, a marker of activated neurons in an experimental model of neuropathic pain (sciatic nerve tying). " 11/01/2007 - "4. These findings suggest that acute administration of AM404 reduces allodynia in a neuropathic pain model via cannabinoid CB(1) receptor activation, without causing the undesirable motor disruption associated with cannabinoid receptor agonists." Order ALL the reference details at left...
4.	Glioma (Gliomas) 04/01/2003 - "In the present study, AM404 and VDM 11 were found to reduce C6 glioma cell proliferation with IC(50) values of 4.9 and 2.7 microM, respectively. " 10/01/2006 - "It is concluded that AM404, VDM11, UCM707 and OMDM2 produce a rapid loss of C6 glioma cell viability over the same concentration range as is required for the inhibition of AEA uptake in vitro, albeit with a longer latency. " 04/01/2003 - "AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide." 10/01/2006 - "In this study, the effects of four commonly used acyl-based uptake inhibitors [N-(4-hydroxyphenyl)arachidonylamide (AM404), N-(4-hydroxy-2-methylphenyl) arachidonoyl amide (VDM11), (5Z,8Z,11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide (UCM707) and (9Z)-N-[1-((R)-4-hydroxybenzyl)-2-hydroxyethyl]-9-octadecen-amide (OMDM2)] and the related compound arvanil on C6 glioma cell viability were investigated. " 05/10/2004 - "Recently, three compounds, UCM707 [N-(Fur-3-ylmethyl)arachidonamide], OMDM-1 and OMDM-2 [the 1'-(S)- and 1'-(R)-enantiomers of the 1'-4-hydroxybenzoyl analogue of oleoylethanolamide], selective for the uptake process, have been described and we have used these compounds, together with AM404 [(N-(4-hydroxyphenyl) arachidonoyl amide)] and VDM11 [(5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide]), with the initial aim of determining which mechanism of uptake predominates in C6 glioma and RBL-2H3 cells. " Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 04/01/2005 - "In the present study, it has been demonstrated that in the presence of a low (0.1%, w/v) concentration of fatty acid-free bovine serum albumin, a temperature-dependent and saturable (K(m) approximately 1 microM) uptake of anandamide into P19 embryonic carcinoma cells can be demonstrated using an incubation time of 4 min. Under these conditions, the uptake of anandamide at 4 degrees C is low at a substrate concentration of 100 nM. The uptake at 37 degrees C was not significantly reduced following treatment of the cells with either methyl-beta-cyclodextrin (50 microM) or mevinolin (1 microM), but was reduced by the FAAH inhibitor URB597 (1 microM) and inhibited by the transport inhibitor cum FAAH substrate AM404 with an IC(50) value of 12 microM. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Endocannabinoids (Endocannabinoid)
2.	anandamide (arachidonylethanolamide)
3.	Formaldehyde (Formol)
4.	N- (3- furylmethyl)eicosa- 5,8,11,14- tetraenamide
5.	Streptozocin (Streptozotocin)
6.	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)
7.	Freund's Adjuvant
8.	N- (2- methyl- 3- hydroxyphenyl)- 5,8,11,14- eicosatetraenamide
9.	Bovine Serum Albumin
10.	Lovastatin (Mevacor)

Related Therapies and Procedures

1.	Ligation
2.	Analgesia
3.	Injections

Best Treatments:
Research Summary Report
on Hyperalgesia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 236 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>